ECSP18038014A - Bloqueador del canal de sodio - Google Patents
Bloqueador del canal de sodioInfo
- Publication number
- ECSP18038014A ECSP18038014A ECIEPI201838014A ECPI201838014A ECSP18038014A EC SP18038014 A ECSP18038014 A EC SP18038014A EC IEPI201838014 A ECIEPI201838014 A EC IEPI201838014A EC PI201838014 A ECPI201838014 A EC PI201838014A EC SP18038014 A ECSP18038014 A EC SP18038014A
- Authority
- EC
- Ecuador
- Prior art keywords
- sodium channel
- channel blocker
- present
- prevention
- pharmaceutically acceptable
- Prior art date
Links
- 239000003195 sodium channel blocking agent Substances 0.000 title abstract 2
- 229940125794 sodium channel blocker Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un compuesto representado por la Fórmula Química, o una sal farmacéuticamente aceptable del mismo. El compuesto según la presente invención puede usarse de manera útil para la prevención o el tratamiento de enfermedades relacionadas con bloqueantes de canales de sodio.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150159637 | 2015-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP18038014A true ECSP18038014A (es) | 2018-05-31 |
Family
ID=58695815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201838014A ECSP18038014A (es) | 2015-11-13 | 2018-05-18 | Bloqueador del canal de sodio |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10227338B2 (es) |
| EP (1) | EP3375782B1 (es) |
| JP (1) | JP6559894B2 (es) |
| KR (1) | KR102245930B1 (es) |
| CN (1) | CN108349963B (es) |
| AU (1) | AU2016351526B2 (es) |
| BR (1) | BR112018009754B1 (es) |
| CA (1) | CA3003119C (es) |
| CL (1) | CL2018001281A1 (es) |
| CO (1) | CO2018005064A2 (es) |
| EC (1) | ECSP18038014A (es) |
| ES (1) | ES2821962T3 (es) |
| HR (1) | HRP20201695T1 (es) |
| HU (1) | HUE052569T2 (es) |
| MA (1) | MA43231B1 (es) |
| MX (1) | MX376469B (es) |
| MY (1) | MY194015A (es) |
| NZ (1) | NZ742069A (es) |
| PE (1) | PE20181301A1 (es) |
| PH (1) | PH12018500999A1 (es) |
| PL (1) | PL3375782T3 (es) |
| PT (1) | PT3375782T (es) |
| RS (1) | RS60927B1 (es) |
| RU (1) | RU2705578C1 (es) |
| SA (1) | SA518391540B1 (es) |
| SG (1) | SG11201803867TA (es) |
| SI (1) | SI3375782T1 (es) |
| TN (1) | TN2018000157A1 (es) |
| WO (1) | WO2017082688A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019007763A2 (pt) * | 2016-10-17 | 2019-07-02 | Genentech Inc | composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção |
| TW202003490A (zh) * | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| CN110885319B (zh) * | 2018-09-10 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
| CN112759559B (zh) * | 2019-11-06 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5464853A (en) | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| JP3555620B2 (ja) * | 2001-03-12 | 2004-08-18 | 小野薬品工業株式会社 | Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 |
| JP2006290791A (ja) | 2005-04-11 | 2006-10-26 | Astellas Pharma Inc | アゾール置換スルホニルベンゼン誘導体 |
| EP1901747A2 (en) * | 2005-05-25 | 2008-03-26 | Ingenium Pharmaceuticals AG | Pyrimidine-based cdk inhibitors for treating pain |
| EP2032539A4 (en) | 2006-06-09 | 2011-03-16 | Merck Sharp & Dohme | BENZAZEPINONE AS SODIUM CHANNEL BLOCKER |
| EP2139852A1 (en) * | 2006-12-19 | 2010-01-06 | Pharmos Corporation | Sulfonamide derivatives with therapeutic indications |
| SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| JP2008290791A (ja) * | 2007-05-22 | 2008-12-04 | Funai Electric Co Ltd | 画像形成装置 |
| JP5460589B2 (ja) * | 2007-07-13 | 2014-04-02 | アイカジェン， インコーポレイテッド | ナトリウムチャネル阻害物質 |
| CA2747419C (en) * | 2009-01-12 | 2014-07-08 | Icagen, Inc. | Sulfonamide derivatives |
| JP2013532184A (ja) * | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体 |
| MX2014005304A (es) * | 2011-10-31 | 2015-03-20 | Xenon Pharmaceuticals Inc | Biaril eter sulfonamidas y su uso como agentes terapeuticos. |
| WO2013086229A1 (en) | 2011-12-07 | 2013-06-13 | Amgen Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| ES2593533T3 (es) | 2011-12-15 | 2016-12-09 | Pfizer Limited | Derivados de sulfonamida |
| WO2013093688A1 (en) | 2011-12-19 | 2013-06-27 | Pfizer Limited | Sulfonamide derivatives and use thereof as vgsc inhibitors |
| CA2874621A1 (en) | 2012-05-22 | 2013-11-28 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
| US9376429B2 (en) * | 2012-10-15 | 2016-06-28 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blockers, preparation method thereof and use thereof |
| US20170145003A1 (en) * | 2014-02-27 | 2017-05-25 | Mark G. DeGiacomo | Heterocyclic inhibitors of the sodium channel |
-
2016
- 2016-11-11 SG SG11201803867TA patent/SG11201803867TA/en unknown
- 2016-11-11 KR KR1020160150511A patent/KR102245930B1/ko active Active
- 2016-11-11 PT PT168646149T patent/PT3375782T/pt unknown
- 2016-11-11 MY MYPI2018000662A patent/MY194015A/en unknown
- 2016-11-11 AU AU2016351526A patent/AU2016351526B2/en active Active
- 2016-11-11 RU RU2018119954A patent/RU2705578C1/ru active
- 2016-11-11 PE PE2018000765A patent/PE20181301A1/es unknown
- 2016-11-11 MX MX2018005940A patent/MX376469B/es active IP Right Grant
- 2016-11-11 ES ES16864614T patent/ES2821962T3/es active Active
- 2016-11-11 CA CA3003119A patent/CA3003119C/en active Active
- 2016-11-11 NZ NZ742069A patent/NZ742069A/en unknown
- 2016-11-11 MA MA43231A patent/MA43231B1/fr unknown
- 2016-11-11 TN TNP/2018/000157A patent/TN2018000157A1/en unknown
- 2016-11-11 SI SI201630902T patent/SI3375782T1/sl unknown
- 2016-11-11 HR HRP20201695TT patent/HRP20201695T1/hr unknown
- 2016-11-11 RS RS20201235A patent/RS60927B1/sr unknown
- 2016-11-11 EP EP16864614.9A patent/EP3375782B1/en active Active
- 2016-11-11 JP JP2018524451A patent/JP6559894B2/ja active Active
- 2016-11-11 BR BR112018009754-3A patent/BR112018009754B1/pt active IP Right Grant
- 2016-11-11 HU HUE16864614A patent/HUE052569T2/hu unknown
- 2016-11-11 PL PL16864614.9T patent/PL3375782T3/pl unknown
- 2016-11-11 CN CN201680066269.7A patent/CN108349963B/zh active Active
- 2016-11-11 US US15/771,775 patent/US10227338B2/en active Active
- 2016-11-11 WO PCT/KR2016/013029 patent/WO2017082688A1/ko not_active Ceased
-
2018
- 2018-05-08 PH PH12018500999A patent/PH12018500999A1/en unknown
- 2018-05-09 SA SA518391540A patent/SA518391540B1/ar unknown
- 2018-05-10 CL CL2018001281A patent/CL2018001281A1/es unknown
- 2018-05-11 CO CONC2018/0005064A patent/CO2018005064A2/es unknown
- 2018-05-18 EC ECIEPI201838014A patent/ECSP18038014A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020014586A2 (es) | Compuestos | |
| DOP2020000112A (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| MX380394B (es) | Compuesto novedoso de bifenilo o una sal del mismo. | |
| CO2019004034A2 (es) | Compuesto de piridina | |
| MX2022005160A (es) | Oxisteroles y metodos de uso de los mismos. | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| DOP2015000201A (es) | Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos | |
| MX2016011160A (es) | Tratamiento de afecciones asociadas con la hiperinsulinemia. | |
| CL2018002583A1 (es) | Derivado de morfolina | |
| CR20150325A (es) | Compuestos trcíclicos para inhibir el canal cftr | |
| AR095097A1 (es) | Compuestos de fenoxietoxi | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| ECSP18009366A (es) | Antagonistas del receptor de cgrp | |
| MX394782B (es) | Compuestos para el tratamiento de enfermedades asociadas con una disfunción mitocondrial. | |
| CO2018005064A2 (es) | Bloqueador del canal de sodio | |
| SV2019005838A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| MX2017006110A (es) | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. | |
| AR110770A1 (es) | Moduladores del canal de potasio | |
| MX2022006984A (es) | Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina. | |
| PH12017501404A1 (en) | Diaza-benzofluoranthrene compounds | |
| MX2022000651A (es) | Proceso mejorado para preparar ozanimod. | |
| AR115865A2 (es) | Compuestos terapéuticos | |
| MX2018007796A (es) | Compuestos de fenilimidazol. | |
| UY36096A (es) | Inhibir el canal de iones del potencial del receptor transitorio a1 |